News — TheraMe

TheraMe! High impact

News

15.10.2025

We welcome three new team members to TheraMe!. Their expertise will strengthen our innovation and help drive the next stage of growth

23.01.2025

Press release: CSEM and TheraMe! collaboration revolutionizing cancer therapy with personalized drug screening technology

10.12.2024

It was a privilege to pitch at the EPFL Investor Day event, where we gained valuable insights, built strategic relationships

01.11.2024

We are excited to welcome Mehmet Sehir to our team as a Bioinformatician, bringing his skills in NGS data analysis and algorithm development

25.04.2024

T heraMe! was honored to be one of the 20 startups selected to pitch the Startup Champions Seed Night, showcasing our innovative solutions to over 500 attendee

24.01.2024

TheraMe! is awarded an Innosuisse grant for the development of an industry prototype in collaboration with CSEM

15.12.2023

TheraMe! unveils an enhanced prototype for streamlined IVD screens

11.05.2023

TheraMe! wins audience award at AGORA BioInnovation day

14.04.2022

TheraMe! selected among 10 finalists in the Health & Nutrition vertical of the Venture 2022 competition

01.11.2021

EPFL host lab receives prestigious PHRT grant for TheraMe! groundbreaking cancer therapy project

16.08.2021

Kick-off for the Innovative "TheraMe!" Innosuisse project

Publications

Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets. Nat Commun 13, 4450 (2022). Mathur, L., Szalai, B., Du, N.H. et al.

Technological and computational advances driving high-throughput oncology. Trends Cell Biol. 2022 Nov;32(11):947-961. Kolmar L, Autour A, Ma X, Vergier B, Eduati F, Merten CA.

A microfluidic Braille valve platform for on-demand production, combinatorial screening and sorting of chemically distinct droplets. Utharala, R*., Grab, A*., Vafaizadeh, V*. et al. Nat Protoc (2022), * Contributed equally.

Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Eduati F, Jaaks P, Wappler J, Cramer T, Merten CA, Garnett MJ, Saez-Rodriguez J. Molecular Systems Biology (16)e8664: 1-13, 2020

Microfluidics as an Enabling Technology for Personalized Cancer Therapy. Mathur L*, Ballinger M*, Utharala R*, Merten CA. Small. E1904321: 1-18, 2019

A microfluidics platform for combinatorial drug screening on cancer biopsies. Eduati F*, Utharala R*, Madhavan D, Neumann UP, Longerich T, Cramer T, Saez-Rodriguez J, Merten CA. Nature Communications. 9(1):2434: 1-13, 2018